Clinical Trial Update: Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab with induction chemotherapy in resectable non-small cell lung cancer was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Pemetrexed (pemetrexed)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2026-02-20